Abstract
Numerous types of nanoparticles are being designed for systemic and targeted drug delivery. However, keeping nanoparticles in blood for sufficiently long times so as to allow them to reach their therapeutic target is a major challenge. Upon administration into blood, nanoparticles are quickly opsonized and cleared by the macrophages, thereby limiting their circulation times. Surface-modification of nanoparticles by PEG was developed as the first strategy to prolong nanoparticle circulation. While PEGylation has helped prolong particle circulation, it has several limitations including transient nature of the effect and compromised particle-target interactions. Accordingly, several other approaches have been developed to prolong nanoparticle circulation in blood. These include modification with CD47, modulation of mechanical properties, engineering particle morphology and hitchhiking on red blood cells. In this review, we discuss the factors that affect nanoparticle circulation time and discuss recent progress in development of strategies to prolong circulation time.
Keywords: Nanotechnology, targeting, long-circulation, macrophage, half-life, nanomedicine
Current Pharmaceutical Design
Title: Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects
Volume: 16 Issue: 21
Author(s): Jin-Wook Yoo, Elizabeth Chambers and Samir Mitragotri
Affiliation:
Keywords: Nanotechnology, targeting, long-circulation, macrophage, half-life, nanomedicine
Abstract: Numerous types of nanoparticles are being designed for systemic and targeted drug delivery. However, keeping nanoparticles in blood for sufficiently long times so as to allow them to reach their therapeutic target is a major challenge. Upon administration into blood, nanoparticles are quickly opsonized and cleared by the macrophages, thereby limiting their circulation times. Surface-modification of nanoparticles by PEG was developed as the first strategy to prolong nanoparticle circulation. While PEGylation has helped prolong particle circulation, it has several limitations including transient nature of the effect and compromised particle-target interactions. Accordingly, several other approaches have been developed to prolong nanoparticle circulation in blood. These include modification with CD47, modulation of mechanical properties, engineering particle morphology and hitchhiking on red blood cells. In this review, we discuss the factors that affect nanoparticle circulation time and discuss recent progress in development of strategies to prolong circulation time.
Export Options
About this article
Cite this article as:
Yoo Jin-Wook, Chambers Elizabeth and Mitragotri Samir, Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects, Current Pharmaceutical Design 2010; 16 (21) . https://dx.doi.org/10.2174/138161210791920496
DOI https://dx.doi.org/10.2174/138161210791920496 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases
Current Pharmaceutical Design Potential Advantages of Using Synchrotron X-ray Based Techniques in Pediatric Research
Current Medicinal Chemistry Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Recent Advances in Radiation Therapy of Cancer Cells: A Step towards an Experimental and Systems Biology Framework
Current Radiopharmaceuticals The University of New Mexico Center for Molecular Discovery
Combinatorial Chemistry & High Throughput Screening Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Current Development in Encapsulated Cell Therapy for Degenerative Retinopathies
Current Tissue Engineering (Discontinued) NADPH Oxidases NOXs and DUOXs as Putative Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry New N’-Arylidene-2-[(4-Nitrophenyl)Piperazın-1-yl]Acetohydrazide Derivatives: Synthesis and Anticancer Activity Investigation
Letters in Drug Design & Discovery Modulation of Matrix Metalloproteinases by Plant-derived Products
Current Cancer Drug Targets Bioprocessing of Baculovirus Vectors: A Review
Current Gene Therapy Optimal Saturated Neuropilin-1 Expression in Normal Tissue Maximizes Tumor Exposure to Anti-Neuropilin-1 Monoclonal Antibody
Anti-Cancer Agents in Medicinal Chemistry Expression and Function of Bcl-2 Proteins in Melanoma
Current Genomics The Interest of Folic Acid in Targeted Photodynamic Therapy
Current Medicinal Chemistry The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets Role of Pancreatic β-Cell Death and Cell Death-Associated Inflammation in Diabetes
Current Molecular Medicine T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation
Current Gene Therapy Repurposing Pharmaceuticals as Neuroprotective Agents for Cerebral Malaria
Current Clinical Pharmacology Editorial (Thematic Issue: Engineered Magnetic Core@Shell Structures)
Current Pharmaceutical Design Cholesterol in Alzheimers Disease: Unresolved Questions
Current Alzheimer Research